Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.65 |
| ▸ | FNTB | P49356 | 8/20 | 0.65 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723122 | 0.90 | FNTA (0.55) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL3375607 | 0.90 | FNTA (0.56) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL1722397 | 0.87 | MEN1 (0.61) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL2212615 | 0.84 | FNTA (0.51) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL3376298 | 0.82 | FNTA (0.48) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL3275261 | 0.81 | PTGES (0.59) | PTGESALOX5ALDH1A1LMNANR1I2 | |
| SCHEMBL15124140 | 0.81 | FNTA (0.65) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL303692 | 0.80 | LMNA (0.66) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL1723202 | 0.79 | FNTA (0.45) | FNTAFNTBPGGT1BMEN1KMT2A | |
| SCHEMBL1723280 | 0.78 | KMT2A (0.49) | FNTAFNTBMEN1KMT2APTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | FNTA 4175/4885FNTB 2708/4885PGGT1B 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.